Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Chevallier, Patrice  [Clear All Filters]
Journal Article
Cesaro S, Tridello G, Knelange NSimone, Blijlevens N, Martin M, Snowden JA, Malladi R, Ljungman P, Deconinck E, Gedde-Dahl T, et al. Impact of early candidemia on the long-term outcome of allogeneic hematopoietic stem cell transplant in non-leukemic patients: an outcome analysis on behalf of IDWP-EBMT. Bone Marrow Transplant. 2021.
Battipaglia G, Labopin M, Blaise D, Díez-Martín JLuis, Bazarbachi A, Vitek A, Chevallier P, Castagna L, Grillo G, Daguindau E, et al. Impact of the addition of antithymocyte globulin to post-transplant cyclophosphamide in haploidentical transplantation with peripheral blood compared to post-transplant cyclophosphamide alone in acute myeloid leukemia: a retrospective study on behalf of t. Transplant Cell Ther. 2022.
Bouard L, Guillaume T, Peterlin P, Garnier A, Le Bourgeois A, Duquenne A, Mahe B, Dubruille V, Blin N, Touzeau C, et al. Influence of donor type (sibling vs matched-unrelated donor vs haplo-identical donor) on outcomes after clofarabine-based reduced-intensity conditioning allograft for myeloid malignancies. Biol Blood Marrow Transplant. 2019.
Chalandon Y, Rousselot P, Chevret S, Cayuela J-M, Kim R, Huguet F, Chevallier P, Graux C, Thiebaut-Bertrand A, Chantepie SP, et al. Nilotinib with or without cytarabine for Philadelphia positive acute lymphoblastic leukemia. Blood. 2024.
Legrand N, Salameh P, Jullien M, Chevallier P, Ferron E, David G, Devilder M-C, Willem C, Gendzekhadze K, Parham P, et al. Non-Expressed Donor KIR3DL1 Alleles May Represent a Risk Factor for Relapse after T-Replete Haploidentical Hematopoietic Stem Cell Transplantation. Cancers (Basel). 2023;15(10).
Paviglianiti A, Maio KTozatto, Rocha V, Gehlkopf E, Milpied N, Esquirol A, Chevallier P, Blaise D, Gac A-C, Leblond V, et al. Outcomes of advanced Hodgkin lymphoma after umbilical cord blood transplantation: a Eurocord and EBMT Lymphoma and Cellular Therapy & Immunobiology Working Party study. Biol Blood Marrow Transplant. 2018.
Xavier E, Cornillon J, Ruggeri A, Chevallier P, Cornelissen JJ, Andersen NS, Maillard N, Nguyen S, Blaise D, Deconinck E, et al. Outcomes of Cord Blood Transplantation Using Reduced Intensity Conditioning for Chronic Lymphocytic Leukemia: a Study on Behalf of Eurocord and Cord Blood Committee of Celular Therapy and Immunobiology Working Party(CTIWP), Chronic Malignancies Working Pa. Biol Blood Marrow Transplant. 2015.
Baron F, Ruggeri A, Peczynski C, Labopin M, Bourhis J-H, Michallet M, Chevallier P, Sanz J, Forcade E, Saccardi R, et al. Outcomes of graft failure after umbilical cord blood transplantation in acute leukemia: a study from Eurocord and the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplant. 2023.
Lepretre S, Touzart A, Vermeulin T, Picquenot J-M, Tanguy-Schmidt A, Salles G, Lamy T, Béné M-C, Raffoux E, Huguet F, et al. Pediatric-Like Acute Lymphoblastic Leukemia Therapy in Adults With Lymphoblastic Lymphoma: The GRAALL-LYSA LL03 Study. J Clin Oncol. 2015.
Peric Z, Cahu X, Malard F, Brissot E, Chevallier P, Guillaume T, Gregoire M, Gaugler B, Mohty M. Peripheral blood plasmacytoid dendritic cells at day 100 can predict outcome after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2015.
Jullien M, Guillaume T, Le Bourgeois A, Peterlin P, Garnier A, Eveillard M, Le Bris Y, Bouzy S, Tessoulin B, Gastinne T, et al. Phase I study of zoledronic acid combined with escalated doses of interleukine-2 for early in vivo generation of Vγ9Vδ2 T-cells after haploidentical stem cell transplant with posttransplant cyclophosphamide. Am J Hematol. 2024.
Le Bourgeois A, Jullien M, Garnier A, Peterlin P, Béné MC, Guillaume T, Chevallier P. Post-transplant cyclophosphamide as sole GHVD prophylaxis after matched reduced-intensity conditioning allotransplant. Clin Transl Med. 2023;13(4):e1242.
Battipaglia G, Labopin M, Hamladji R-M, Blaise D, Chevallier P, Brissot E, Gerbitz A, Socié G, Afanasyev B, Ciceri F, et al. Post-transplantation cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLA-identical sibling donors: A retrospective analysis from the Acute Leukemia Working Party o. Cancer. 2020.
Guillaume T, Thépot S, Peterlin P, Ceballos P, Le Bourgeois A, Garnier A, Orvain C, Giltat A, François S, Le Bris Y, et al. Prophylactic or preemptive low-dose azacitidine and donor lymphocyte infusion to prevent disease relapse following allogeneic transplantation in patients with high risk acute myeloid leukemia or myelodysplastic syndrome. Transplant Cell Ther. 2021.
Chevallier P, Labopin M, Socié G, Tabrizi R, Furst S, Lioure B, Guillaume T, Delaunay J, de la Tour RPeffault, Vigouroux S, et al. Results from a clofarabine-busulfan containing reduced-toxicity conditioning regimen prior to allogeneic stem cell transplantation: the phase II prospective CLORIC trial. Haematologica. 2014.
Dhedin N, Huynh A, Maury S, Tabrizi R, Beldjord K, Asnafi V, Thomas X, Chevallier P, Nguyen S, Coiteux V, et al. Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia. Blood. 2015.
Kharfan-Dabaja MA, Labopin M, Brissot E, Kröger N, Finke J, Ciceri F, Deconinck E, Blaise D, Chevallier P, Gramatzki M, et al. Second allogeneic haematopoietic cell transplantation using HLA-matched unrelated versus T-cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia. Br J Haematol. 2021.
Le Bourgeois A, Labopin M, Marçais A, de Latour RPeffault, Blaise D, Chantepie S, N'Guyen S, Maillard N, Forcade E, Yakoub-Agha I, et al. Sequential allogeneic hematopoietic stem cell transplantation for active refractory/relapsed myeloid malignancies: results of a reduced-intensity conditioning preceded by clofarabine and cytosine arabinoside, a retrospective study on behalf of the SFGM-TC. Ann Hematol. 2020.
Guillaume T, Dehame V, Chevallier P, Peterlin P, Garnier A, Gregoire M, Pichinuk E, Rubinstein DB, Wreschner DH. Targeting cell-bound MUC1 on myelomonocytic, monocytic leukemias and phenotypically defined leukemic stem cells with anti-SEA module antibodies. Exp Hematol. 2018.
Hirschbühl K, Labopin M, Polge E, Blaise D, Bourhis JHenri, Socié G, Forcade E, Yakoub-Agha I, Labussière-Wallet H, Bethge W, et al. Total body irradiation versus busulfan based intermediate intensity conditioning for stem cell transplantation in ALL patients >45 years-a registry-based study by the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplant. 2023.

Pages